Browse drugs

…pid/cholesterol pathways. Transcriptomic analysis revealed that EGC treatment suppressed SREBP signaling, cholesterol metabolism an…

…=111,357; e.g., empagliflozin, dapagliflozin, canagliflozin) or DPP4is (n=43,868; e.g., sitagliptin, linagliptin) without cross-exposu…

… was recently withdrawn from the US creating a therapeutic gap. Seladelpar (SEL), approved in 2024 in the US for patients with PBC and an …

… adult cardiomyocytes were used as in vitro and in vivo models. Butylmalonate prodrugs were synthesized and tested. Isolated mitochondria wer…

… 0.652), but not in those without DU. The protective effects of bosentan were confirmed in all sensitivity analyses targeting PAH detect…

…citinib or upadacitinib), rituximab, tocilizumab, methotrexate, mycophenolate mofetil, or glucocorticoids (>=10 mg prednisone equivalent daily) for m…

…pse risk (1.35, 1.16 to 1.57) and RAW (1.77, 1.07 to 2.94) than ocrelizumab. Alemtuzumab was associated with higher ARR (0.18 vs 0.12, p<0.…

… exposure to buprenorphine versus methadone, further supporting buprenorphine as a safe treatment option for opioid use disorder during pregn…

… Internal trust guideline.2024.Patel J, Lucas C, Ryan J, et al. Vancomycin therapeutic drug monitoring in paediatrics. Paediatr Child Heal…

…le therapeutic options, anti-TNFα monoclonal antibodies such as infliximab (IFX) and adalimumab (ADA) are widely used in moderate-to-sever…

…n 14.9 g/L, elevated bilirubin, and liver enzyme abnormalities. Sirolimus 1 mg daily was initiated. After 5 days, the sirolimus trough le…

…lin.Material and methods Over four weeks (February–March 2025), insulin prescriptions from adult medical wards (excluding intensive car…